A new initiative from the Food and Drug Administration’s Oncology Center of Excellence (OCE) attempts to improve access to oncology clinical trials for patients from historically marginalized groups, including racial and ethnic minorities, rural populations, and those facing barriers to accessing health care. But what does the OCE Equity Program mean for medtech innovators? Physician Michel van Harten, whose company myTomorrows utilizes AI to connect patients and physicians with relevant clinical trials, shared his thoughts on the program with Medtech Insight.
Physician And myTomorrows CEO Discusses FDA’s New Program To Advance Clinical Trial Diversity
The US FDA recently announced a new initiative aimed at improving access to cancer trials among traditionally underserved populations. myTomorrows CEO Michel van Harten talked to Medtech Insight about how the agency’s plan might reshape the landscape of clinical trials going forward.
More from Regulation
More from Policy & Regulation
• By
Exer Labs Inc.’s website marketed its AI-based Exer Scan app to “screen and treat Parkinson’s, TB, Cerebral Palsy and more.” But those claims went well beyond what was allowed under the product’s 510(k) clearance, US regulators say.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
People living with diabetes who receive continuous glucose monitors (CGMs) through medical supply firms show higher compliance, lower costs of care, and fewer hospitalizations after one year than those who use pharmacies, a new study shows.